Search - tctmd.com

Displaying 61 - 80 of 148

Sort: Relevancy | Date

News Daily News

FDA Passes on Inclisiran, Citing Manufacturing Site Problems

Shelley Wood

December 23, 2020

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

News Daily News

More Insights Into AAA Genetics Spur New Questions on Screening

Caitlin E. Cox

September 29, 2020

News Daily News

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

Yael L. Maxwell

September 14, 2020

News Daily News

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

Yael L. Maxwell

August 27, 2020

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

News Daily News

PAD Patients Undertreated With Statins Despite Elevated CV Risk

L.A. McKeown

July 13, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Todd Neale

May 06, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

Caitlin E. Cox

November 25, 2019

News Daily News

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Michael O'Riordan

November 11, 2019

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

Advertisement

FDA Passes on Inclisiran, Citing Manufacturing Site Problems

Inclisiran Approved in Europe for Lowering LDL Cholesterol

More Insights Into AAA Genetics Spur New Questions on Screening

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

PAD Patients Undertreated With Statins Despite Elevated CV Risk

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Recurrent Events Common Among Young Patients With CAD

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content